- Women in menopause or perimenopause in India try 12.9 longevity interventions on average, compared with 9.4 globally for the same cohort
- 95% have tried natural remedies, while doctor recommendation remains the leading driver of increased willingness to pay
- 63% consult for hormone-related conditions, the highest rate among the four condition groups tracked in India
Women in menopause or perimenopause in India are among the most highly engaged longevity consumers surveyed, actively trying products, services, technologies, natural remedies and specialised treatments to manage their health as they age. New research from Boston Consulting Group (BCG), however, suggests that the next opportunity for the market lies not simply in generating greater engagement, but in meeting existing demand with clinically credible solutions designed around women’s specific life stages.
BCG’s 2026 study, The $350 Billion Longevity Mismatch in Women’s Health, finds that women in menopause or perimenopause in India have tried 12.9 longevity interventions on average, compared with 11.6 among men and 10.0 among women at other life stages. The figure is also above the 9.4 global average for women in the same life stage. Specialised treatments show a particularly pronounced difference within India, with 69% of women in menopause or perimenopause having tried at least one, compared with 52% of women at other life stages.
Natural remedies are particularly widespread in India. More than 95% of women in menopause or perimenopause have tried at least one, compared with 89% of women at other life stages and 93% of men. Among women in menopause or perimenopause, the corresponding adoption rate is 76% in Germany and 70% in the US.
Yet high adoption does not translate into equally high satisfaction: only 53% of natural-remedy interventions tried by women in menopause or perimenopause in India meet their needs. The similarly high adoption among Indian men suggests that natural-remedy use is a broader characteristic of the Indian market rather than a behaviour unique to menopause.
“Indian women are already highly engaged in managing their health as they age, they are actively trying solutions and seeking care. The opportunity now is to meet that engagement with greater clinical credibility and solutions designed around the life stages women are actually navigating. Doctor recommendation remains the strongest driver of additional spending, underscoring the role health-care providers and companies can play in turning existing demand into better experiences and more relevant solutions,” said Parul Bajaj, India Leader, Marketing, Sales and Pricing, BCG.
That opportunity is reflected directly in what women say would encourage them to spend more. A recommendation from a doctor or health-care provider is the leading driver of increased willingness to pay among women in menopause or perimenopause in India, while products designed specifically for their life stage rank among the top three.
For pharmaceutical, consumer-health and health-care companies, the findings point to an opportunity to combine India’s already high consumer engagement with clinical endorsement and solutions built around women’s changing needs across life stages.
High engagement also extends to the formal health-care system. Among Indian women with hormone-related conditions, 63% consult a doctor—the highest consultation rate among the four condition groups tracked in India, compared with 60% for cardiovascular conditions.
Among those who seek hormone-related care, 72% say they feel taken seriously, compared with 82% among women seeking cardiovascular care. Together with the broader consumer findings, the data point to an opportunity not only to sustain high levels of engagement, but also to strengthen women’s experience once they seek care.
India also differs from the broader global picture on overall satisfaction. Women in menopause or perimenopause report a 58.8% needs-met rate, close to the 60.1% reported by women at other life stages and above the 54.7% reported by men.
India’s rate is also around nine percentage points above the 49.7% global rate for women in the same life stage. This reinforces that India’s story is one of high existing engagement rather than an unusually large overall satisfaction deficit.
The India survey included 976 respondents: 242 women in menopause or perimenopause, 431 women at other life stages and 303 men. Globally, women in perimenopause or menopause spend a median of $84 per month on longevity, more than the other cohorts surveyed, and roughly one-third say they would spend an additional median $108 per month if the right product or service existed. BCG estimates this represents a $350 billion global opportunity
